Back to Search
Start Over
Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience
- Source :
- Cancer. 123(4)
- Publication Year :
- 2016
-
Abstract
- BACKGROUND Individuals with chronic hepatitis B virus infection (HBV) or previously resolved HBV are at increased risk of HBV exacerbation or reactivation when they receive treatment with anti-CD20 monoclonal antibodies (against B-lymphocyte antigen cluster of differentiation 20 [CD20], an activated-glycosylated phosphoprotein) like rituximab (RTX). The objective of the current study was to evaluate the rates of appropriate HBV screening before patients started receiving RTX, at the initiation of HBV treatment, and during HBV flares among an underserved safety-net population. METHODS In total, 244 consecutive adults who received treatment with RTX from 2006 to 2015 at an urban safety-net hospital were evaluated to determine appropriate HBV screening (HBV surface antigen [HBsAg] and HBV total core antibody [HBcAb]) before starting RTX. The initiation of prophylactic antiviral therapy and the development of HBV flares after starting RTX were evaluated. Predictors of appropriate HBV screening were evaluated using multivariate logistic regression models. RESULTS Most patients were women (52.7%; n = 128) and of Hispanic ethnicity (30.7%; n = 74). Before starting RTX, 60.5% (n = 147) of patients received appropriate HBV screening. The HBV screening rates before RTX improved from 14.7% (2006-2009) to 74.7% (2010-2012), and to 87.1% (2013-2015; P
- Subjects :
- Adult
Male
Cancer Research
HBsAg
medicine.medical_specialty
Hepatitis B virus
Exacerbation
medicine.medical_treatment
Population
medicine.disease_cause
03 medical and health sciences
0302 clinical medicine
Hepatitis B, Chronic
Internal medicine
Neoplasms
Ethnicity
Medicine
Humans
Mass Screening
education
Aged
CD20
education.field_of_study
B-Lymphocytes
Hepatitis B Surface Antigens
biology
business.industry
virus diseases
Cancer
Antibodies, Monoclonal
Immunosuppression
Middle Aged
medicine.disease
Antigens, CD20
Hepatitis B Core Antigens
digestive system diseases
Oncology
030220 oncology & carcinogenesis
Immunology
biology.protein
030211 gastroenterology & hepatology
Rituximab
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 10970142
- Volume :
- 123
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Cancer
- Accession number :
- edsair.doi.dedup.....ed02fabb324bc6ed03af026c9ceeceb8